These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 33634012)

  • 1. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
    Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
    Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
    Piao J; Lim HJ; Lee M
    Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
    Huang Y; Shen A
    Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
    Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis.
    Noori M; Yousefi AM; Zali MR; Bashash D
    Front Oncol; 2022; 12():1021859. PubMed ID: 36591463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
    Li S; Chen L; Jiang J
    Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
    Li XS; Li JW; Li H; Jiang T
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
    Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
    Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.